HY001N

· Juventas Cell Therapy Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for HY001N, covering 2025-12-04 to 2025-12-04. Get the full timeline:

Most recent: Clinical Trial Update: A Study of HY001N in the Treatment of Relapsed or Refractory Neurological Autoimmune Diseases [EARLY_Phase 1]